Note 15 - Segment and Geographic Information - Schedule of Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Total revenue		$ 172,809	$ 165,948	$ 486,260	$ 492,715
Segment adjusted operating income (loss)		(14,754)	(15,836)	(188,386)	(56,498)
Amortization of intangibles		12,900	12,200	38,500	36,100
Purchase accounting impact on inventory		0	2,956	0	8,737
Transformation costs (1)	[1]	4,255	21	8,742	(34)
Restructuring charges		2,064	812	10,528	3,773
Impairment of goodwill and intangible assets		0	0	115,975	0
Contingent consideration - fair value adjustments		0	(1,404)	0	(18,549)
Merger and acquisition costs and costs related to share repurchase (2)	[2]	74	219	4,821	12,075
Total operating loss		(14,754)	(15,836)	(188,386)	(56,498)
Interest income, net		8,004	11,347	27,650	32,406
Other income (expense), net		(282)	819	650	(704)
Loss before income taxes		(7,032)	(3,670)	(160,086)	(24,796)
Developed Technology Rights [Member]
Amortization of intangibles		6,316	4,656	18,315	13,725
Other Intangible Assets [Member]
Amortization of intangibles		6,621	7,522	20,136	22,403
Operating Segments [Member]
Segment adjusted operating income (loss)		4,582	(1,079)	(9,820)	(14,292)
Total operating loss		4,582	(1,079)	(9,820)	(14,292)
Sample Management Solutions [Member]
Total revenue		80,673	75,341	233,816	221,838
Restructuring charges				2,600
Sample Management Solutions [Member] | Operating Segments [Member]
Segment adjusted operating income (loss)		3,404	813	981	(8,261)
Total operating loss		3,404	813	981	(8,261)
Multiomics [Member]
Total revenue		63,619	63,846	188,556	187,172
Multiomics [Member] | Operating Segments [Member]
Segment adjusted operating income (loss)		(730)	(3,412)	(7,147)	(10,487)
Total operating loss		(730)	(3,412)	(7,147)	(10,487)
B Medical Systems S.a.r.l. [Member]
Total revenue		28,517	26,761	63,888	83,705
Restructuring charges				4,900
B Medical Systems S.a.r.l. [Member] | Operating Segments [Member]
Segment adjusted operating income (loss)		1,908	1,520	(3,654)	4,456
Total operating loss		1,908	1,520	(3,654)	4,456
Corporate Segment [Member]
Restructuring charges				3,000
Other unallocated corporate expenses		$ 6	$ (25)	$ 49	$ 76

[1] Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company’s operations, processes and systems to permanently alter the Company’s operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company’s 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process & systems re-design.

[2] Includes expenses related to governance-related matters.